Posted by Michael Wonder on 03 Dec 2020
The real worth of cancer drugs
1 December 2020 - In November, 2020, we witnessed one of the most awaited elections in recent times—the USA elected Joe Biden as its new President, and with this decision comes renewed hope for science.
For oncology, we wait in anticipation to see whether the Cancer Moonshot programme, launched in 2016 under the Obama administration and overseen by then Vice-President Biden, will be rebooted.
At the time, Congress had authorised US $1·8 billion in funding for cancer research over a 7-year timeframe, which expires in 2022, making next year's budget review crucial.
